Dr. Patel on Combination Chemotherapy and Immunotherapy in Lung Cancer

Jyoti Patel, MD
Published: Thursday, Sep 28, 2017



Jyoti Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago School of Medicine, discusses combination chemotherapy and immunotherapy in patients with lung cancer.

There are a number of promising ongoing clinical trials combining chemotherapy and immunotherapy in lung cancer, says Patel.

In a phase III trial, the combination of pembrolizumab (Keytruda) with carboplatin and pemetrexed demonstrated a significantly higher response rate than chemotherapy alone, as well as an overall survival benefit. This combination led to the May 2017 FDA approval for patients as a frontline treatment.
 


Jyoti Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago School of Medicine, discusses combination chemotherapy and immunotherapy in patients with lung cancer.

There are a number of promising ongoing clinical trials combining chemotherapy and immunotherapy in lung cancer, says Patel.

In a phase III trial, the combination of pembrolizumab (Keytruda) with carboplatin and pemetrexed demonstrated a significantly higher response rate than chemotherapy alone, as well as an overall survival benefit. This combination led to the May 2017 FDA approval for patients as a frontline treatment.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x